海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
195件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not Recruiting
- A Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Prodromal AD (APECS).
- Prodromal Alzheimer's Disease MedDRA version: 20.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Finland, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Poland, Spain, Switzerland, United Kingdom, United States
- 2015-08-27
Not Recruiting
- A 24-week, international, multi centre, randomised, open label, parallel group, phase IV clinical trial investigating changes in bone formation markers in postmenopausal women with primary osteoporosis treated with either PTH(1-84) or strontium ranelate
- Primary postmenopausal osteoporosis MedDRA version: 9.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausal
- Austria, Spain
- 2007-03-07
Not recruiting
- A randomised control trial of the effect of Niacinamide on Fibroblast Growth factor 23 (FGF23) levels in Chronic Kidney Disease.
- Elevated levels of FGF23 in chronic kidney disease
- ,Outside, New Zealand
- 2013-11-08
Not recruiting
- Open-Label Safety Study of ADS-5102 in PD Patients With LID
- Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease (PD);Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease (PD);Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease (PD);Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease (PD)
- Austria, Canada, France, Germany, Spain, United States
- 2014-07-25
Not Recruiting
- A trial testing two Gilead compounds added to usual therapy for Hepatitis C.
- Chronic Hepatitis C Virus Infection MedDRA version: 14.0 Level: LLT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Austria, Canada, Czech Republic, Germany, Italy, Poland, United Kingdom, United States
- 2010-09-30
Not recruiting
- Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
- Acute Heart Failure;Acute Heart Failure;Acute Heart Failure
- Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States
- 2013-06-03
Not recruiting
- Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome
- Dry Eye Syndromes;Dry Eye Syndromes;Dry Eye Syndromes;Dry Eye Syndromes
- Austria
- 2015-04-26
Not recruiting
- The bone effects of pioglitazone
- Type 2 diabetes mellitus;Osteoporosis
- New Zealand
- 2007-11-28
Not recruiting
- A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects
- Effect of Orally Administrated Moxaverine on Ocular Blood Flow
- Austria
- 2012-06-11
Not Recruiting
- Oral administration of maternal bacteria in twins born by C-section
- Abnormal gut microbiota in infants born by C-section; Abnormal gut microbiota in infants born by C-section;Metabolic and Endocrine - Metabolic disorders;Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
- New Zealand
- 2018-03-06
